LogoLogo
Illumina KnowledgeIllumina SupportSign In
  • Home
  • Overview
    • Welcome
    • What's New
      • Cloud Software Update
      • Local Software Update
  • Configure
    • Configuration
      • Custom Case Data
      • Pipeline and QC Configuration
      • Preferred Transcripts
      • Custom Annotations
      • Disease Configuration
      • Variant Filters
      • Variant Flag Groups
      • Actionability Classifications
      • Report Templates
        • Customizations
      • Report Automation
      • Test Definitions
      • Data Upload
        • Data Upload from User Storage (Connected Insights - Cloud and Connected Insights - Local)
        • Data Upload from ICA or BSSH (Connected Insights - Cloud)
        • Supported Pipelines
          • DRAGEN TruSight Oncology 500 Analysis Software v2.6.0 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.6.0
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.3 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.3
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.2 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.2
          • DRAGEN TruSight Oncology 500 Analysis Software v2.1.1 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.1.1
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.6.1
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.6.0
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.5.0
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.1.1
          • DRAGEN Amplicon v4.3
          • DRAGEN Amplicon v4.2
          • DRAGEN Amplicon v4.1
          • DRAGEN RNA v4.3
          • DRAGEN RNA v4.2
          • DRAGEN RNA v4.1
          • DRAGEN Enrichment v4.3
          • DRAGEN Enrichment v4.2
          • DRAGEN Enrichment v4.1
          • DRAGEN for Illumina cfDNA Prep with Enrichment v4.0.3
          • DRAGEN Somatic Whole Genome v4.3
          • DRAGEN Somatic Whole Genome v4.2
          • DRAGEN Somatic Whole Genome v4.1
          • TruSight Tumor 170 Local App v2.0.1
          • Local Run Manager TruSight Tumor 15 Analysis Module v2.1
        • Custom Pipeline Configuration
          • VCF Input Requirement
          • TMB, MSI, GIS Input Requirement
        • Custom Case Data Upload
    • Upload Assertions
    • Local Installation Guide
      • Overview
      • Prerequisites
      • Download Connected Insights Package
      • Install Connected Insights Software
      • Install License File
      • Sign In to Connected Insights
      • Installation Status Messages
      • Local Configurations
      • Administration Console (Connected Insights - Local)
      • Configure External Storage (Connected Insights - Local)
  • Manage cases
    • Cases Page
    • Cases List
      • Case Metadata Upload
  • Interpret and report
    • Case Page
    • Case Details
      • Merge Cases
    • Overview Tab
      • Classification & Risk Stratification Prediction
    • Visualize Tab
    • Variants Tab
      • Modify Columns
      • Apply Variant Filters
        • Filter by Variant Category
        • Variant Details Filters
        • Variant Quality Filters
        • Functional Impact Filters
        • Disease Association Filters
        • Variant Frequency Filters
        • Flags Filter
        • Filtering Logic
      • IGV Visualizations
    • Lab QC Tab
    • Report Tab
    • View Biomarker Details
      • Biological Classification
      • Actionability
      • Clinical Trials
      • Oncogenicity Prediction
      • Visualize
      • Variant Overview
      • Gene Overview
      • Cancer Datasets
      • Computer Predictors
      • Population
    • Interpret a Biomarker
      • Create Clinical Trials
      • Create Gene Descriptions
      • Manage Assertions
    • Variant Transcripts
    • Add Variant
  • Resources and References
    • Glossary
    • APIs
      • Ingest Cloud Analysis Data API (Connected Insights - Cloud Only)
      • Case APIs
      • Report APIs
      • Audit Log APIs
    • Troubleshooting
      • Overview
      • Audit Log
      • Data Backup (Connected Insights - Local)
      • Software Errors and Corrective Actions
      • How To
      • Technical Assistance
    • Pricing and Usage
    • Security and Compliance
    • Release Notes
Powered by GitBook
On this page

Was this helpful?

Export as PDF
  1. Interpret and report
  2. View Biomarker Details

Oncogenicity Prediction

PreviousClinical TrialsNextVisualize

Last updated 4 months ago

Was this helpful?

The Oncogenicity Prediction feature estimates oncogenic potential of variants based on . The standards include 17 criteria and allow to classify variants into 5 categories: Oncogenic, Likely Oncogenic, Variant of Unknown Significance (VUS), Likely Benign, and Benign. Connected Insights scores variants (only PASS small variants are currently supported) for 16 criteria (with exception of OP2) based on the implementation details provided below.

❗ Use predictions as a starting point for interpretation. Exercise judgement to determine if a greater or fewer number of criteria apply.

Estimated variant oncogenicity can be found:

  • In the column “Oncogenicity Prediction” in the Variants tab available for sorting

  • In the section “Oncogenicity Prediction” in the Biomarker page available for manual review and further interpretation

To view the evidence behind the estimated oncogenicity category and complete variant classification, follow the steps below:

  1. Navigate to the "Oncogenicity Prediction" section in the Biomarker page

  2. Review estimated oncogenicity category, score, and met criteria (displayed with filled checkboxes, see OS2, OM1, OM2, OP3, and OP4 on the figure below)

  3. Review evidence for each criterion by clicking on it and displaying an evidence map. You can move objects on the map to facilitate review.

  4. Select Report to edit and complete variant classification following . Information about met oncogenicity criteria is used to pre-populate variant summary.

\

Implementation Details

OVS1: “Null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a bona fide tumor suppressor gene.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant is a “null variant”. We assess null variants as variants with consequences stop_gained, start_lost, frameshift_variant, splice_acceptor_variant, or splice_donor_variant as well as variants with a high splicing prediction (SpliceAI score > 0.8) regardless of their consequences

  2. Variant is not in the last intron or exon

  3. Variant is in a tumor suppressor gene, according to Cancer Genome Census, CKB, OncoKB or MyKB

\

OS1: “Same amino acid change as a previously established oncogenic variant regardless of nucleotide change. Example: Val→Leu caused by either G>C or G>T in the same codon.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant's consequences are not splice_donor_variant or splice_acceptor_variant

  2. Variant’s splicing prediction is not high (SpliceAI score <= 0.8)

  3. There is a previously established pathogenic / oncogenic or likely pathogenic / oncogenic variant with the same amino acid change but different nucleotide change in ClinVar (2-4 stars) or MyKB

\

OS2: “Well-established in vitro or in vivo functional studies supportive of an oncogenic effect of the variant.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. A variant with the same amino acid change is a gain-, loss-, or switch-of-function variant in MyKB, OncoKB, or CKB, is interpreted as pathogenic / oncogenic or likely pathogenic / oncogenic in MyKB, OncoKB, CKB, or ClinVar (2-4 stars), and OS1 is not applicable OR

  2. A variant with the same nucleotide change is a gain-, loss-, or switch-of-function variant in MyKB, OncoKB, or CKB, is interpreted as pathogenic / oncogenic or likely pathogenic / oncogenic in ClinVar (2-4 stars), and OS1 is applicable

In this implementation, “Well-established in vitro or in vivo functional studies” is inferred based on knowledge bases having records of gain-, loss-, or switch-of-function, usually established based on functional studies. “... supportive of an oncogenic effect of the variant” is established based on the evidence of oncogenicity in knowledge sources.

\

For this criterion, we are checking the fulfillment of the following conditions:

  1. There are at least 50 samples with somatic variants at the same amino acid position in cancerhotspots.org, there are at least 10 samples with variants with the same amino acid change in cancerhotspots.org and OS1 is not applicable OR

  2. There are at least 50 samples with somatic variants at the same amino acid position in COSMIC, there are less than 10 samples with variants with the same amino acid change in cancerhotspots.org and OS1 is not applicable OR

  3. There are at least 50 samples with somatic variants at the same nucleotide position in cancerhotspots.org, there are at least 10 samples with a variant with the same nucleotide change in cancerhotspots.org and OS1 is applicable OR

  4. There are at least 50 samples with somatic variants at the same nucleotide position in COSMIC, there are less than 10 samples with a variant with the same nucleotide change in cancerhotspots.org and OS1 is applicable

\

OM1: “Located in a critical and well-established part of a functional domain (e.g., active site of an enzyme).”

For this criterion, we are checking the fulfillment of the following conditions:

  1. The variant is located in a region of a protein domain where pathogenic variants occur. The regions in each gene are defined by taking all protein domains from UniProt, mapping all pathogenic and likely pathogenic variants in ClinVar to each domain and defining the regions by using the positions of the first and last pathogenic and likely pathogenic variants from ClinVar and adding 2 bp padding on each side.

  2. OS1 and OS3 are not applicable

\

OM2: “Protein length changes as a result of in-frame deletions / insertions in a known oncogene, or tumor suppressor gene or stop-loss variants in a known tumor suppressor gene.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant’s consequence is inframe_deletion or inframe_insertion and it is located in an oncogene or a tumor suppressor gene (based on Cancer Genome Census, CKB, OncoKB or MyKB) or variant’s consequence is stop-lost and it is located in a tumor suppressor gene per the same sources

  2. OVS1 is not applicable

\

For this criterion, we are checking the fulfillment of the following conditions:

  1. There are less than 50 samples with somatic variants at the same amino acid position in cancerhotspots.org, there are at least 10 samples with variants with the same amino acid change in cancerhotspots.org , and OM1 and OM4 are not applicable OR

  2. There are 10 - 49 samples with somatic variants at the same amino acid position and change in COSMIC, there are less than 10 samples with variants with the same amino acid change in cancerhotspots.org , and OM1 and OM4 are not applicable

\

OM4: “Missense variant at an amino acid residue where a different missense variant determined to be oncogenic (using this standard) has been documented. Amino acid difference from reference amino acid should be greater or at least approximately the same as for missense change determined to be oncogenic.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. There is a missense variant at the same amino acid position with a different amino acid change interpreted as pathogenic / oncogenic or likely pathogenic / oncogenic in ClinVar (2-4 stars), OncoKB or MyKB

  2. OS1, OS3 and OM1 are not applicable

\

OP1: “All utilized lines of computational evidence support an oncogenic effect of a variant (conservation / evolutionary, splicing impact, etc.).”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant’s effect predicted to be damaging (REVEL > 0.75 and PrimateAI-3D score percentile > 0.8) or variant’s splicing prediction is high (SpliceAI score > 0.8)

\

OP2: “Somatic variant in a gene in a malignancy with a single genetic etiology.”

This criterion is not yet implemented.

\

For this criterion, we are checking the fulfillment of the following conditions:

  1. There is at least 1 sample with a somatic variant at the same amino acid position in cancerhotspots.org or COSMIC

  2. There are less than 10 samples with variants with the same amino acid change in both, cancerhotspots.org and COSMIC

\

OP4: “Absent from controls (or at an extremely low frequency) in Genome Aggregation Database (gnomAD).”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant’s allele count in the global population (gnomAD) is less than 10 if the variant is not in TP53, KRAS, or PTEN

  2. Variant is absent in the global population (gnomAD) if the variant is in TP53 or KRAS

  3. Variant’s frequency in the global population is less than 0.001% (gnomAD) if the variant is in PTEN

\

SBVS1: “Minor allele frequency is >5% in Genome Aggregation Database (gnomAD) in any of 5 general continental populations: African, East Asian, European (Non-Finnish), Latino, and South Asian.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant’s frequency in any one population is over 5% (gnomAD) if the variant is not in TP53, KRAS or PTEN

  2. Variant’s frequency in the global population is equal or over 0.1% (gnomAD) and allele count in the global population is equal or over 5 (gnomAD) if the variant is in TP53

  3. Variant’s frequency in the global population is equal or over 0.05% (gnomAD) if the variant is in KRAS

  4. Variant’s frequency in the global population is equal or over 1% (gnomAD) and allele count in the global population is equal or over 5 (gnomAD) if the variant is in PTEN

\

SBS1: “Minor allele frequency is >1% in Genome Aggregation Database (gnomAD) in any of 5 general continental populations: African, East Asian, European (Non-Finnish), Latino, and South Asian.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant’s frequency in any one population is over 1% (gnomAD) if the variant is not in TP53, KRAS or PTEN

  2. Variant’s frequency in the global population is over 0.03% (gnomAD) and allele count in the global population is equal or over 5 (gnomAD) if the variant is in TP53

  3. Variant’s frequency in the global population is equal or over 0.025% (gnomAD) if the variant is in KRAS

  4. Variant’s frequency in the global population is equal or over 0.1% (gnomAD) and allele count in the global population is equal or over 5 (gnomAD) if the variant is in PTEN

\

SBS2: “Well-established in vitro or in vivo functional studies show no oncogenic effects.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant is interpreted as benign or likely benign in ClinVar (2-4 stars), OncoKB or MyKB

\

SBP1: “All used lines of computational evidence suggest no effect of a variant (conservation / evolutionary, splicing effect, etc.).”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant’s effect predicted to be neutral (REVEL is equal or less than 0.75 and PrimateAI-3D score percentile is equal or less than 0.8)

  2. Variant’s splicing prediction is low or unknown (SpliceAI score is equal or less than 0.2 or unknown)

\

SBP2: “A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.”

For this criterion, we are checking the fulfillment of the following conditions:

  1. Variant has a consequence synonymous_variant

  2. Variant’s conservation prediction score is not high (PhyloP < 0.1)

  3. Variant’s splicing prediction is low or unknown (SpliceAI score <= 0.2)

OS3: “Located in one of the hotspots in with at least 50 samples with a somatic variant at the same amino acid position, and the same amino acid change count in cancerhotspots.org in at least 10 samples.”

OM3: “Located in one of the hotspots in with less than 50 samples with a somatic variant at the same amino acid position, and the same amino acid change count in cancerhotspots.org is at least 10.”

OP3: “Located in one of the hotspots in and the particular amino acid change count in cancerhotspots.org is below 10.”

cancerhotspots.org
cancerhotspots.org
cancerhotspots.org
Standards for the classification of somatic variants in cancer (Horak et al., Genet Med. 2022)
Interpret a Variant
Oncogenicity Prediction Section on the Biomarker Page